Explore the latest in cervical cancer, including the epidemiology, prevention, screening, and management of cervical dysplasia and neoplasia.
This cohort study compares proportions of women in provincial prison vs women in the general population who were up-to-date for cervical cancer screening between 2006 and 2013 in Ontario, Canada.
This prospective cohort study evaluates the 5-year risk of cervical precancer following p16/ki-67 dual-stain triage of HPV-positive women.
This registry-based cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) database investigates the risk of human papillomavirus (HPV)–associated second primary cancers among survivors of HPV-associated index cancers and tests the hypothesis that the risk of HPV-associated second primary cancer has increased over the last 4 decades.
This cohort study investigates overall survival among patients with newly diagnosed metastatic cervical cancer who received chemotherapy alone compared with those who received chemotherapy and pelvic radiation therapy.
This JAMA Patient Page describes the US Preventive Services Task Force’s recommendations on screening for cervical cancer.
This modeling study uses a microsimulation model of a hypothetical cohort to model the benefits, burden, and harms of cervical cancer screening strategies to inform the 2018 US Preventive Services Task Force Recommendation Statement on screening for cervical cancer in primary care.
This systematic review to support the 2018 US Preventive Services Task Force Recommendation Statement on screening for cervical cancer summarizes published evidence on the benefits and harms of using high-risk human papillomavirus (hrHPV) testing alone, hrHPV testing with cytology, or cytology alone for cervical cancer screening.
This 2018 Recommendation Statement from the US Preventive Services Task Force makes recommendations regarding use of cervical cytology alone, high-risk HPV testing alone, and both in combination to screen for cervical cancer.
This phase1/2 trial evaluates the safety and antitumor activity of ipilimumab in women with recurrent cervical cancer.
This study characterizes the prevalence of human papillomavirus 16 (HPV-16) and HPV-18 metastatic cervical cancers among National Cancer Institute (NCI) trial participants and the cross-reactivity of archived T cells between the 2 HPV types to determine whether treating patients with an HPV-16–targeted vaccine would be effective for women with HPV-18 cancers.
This randomized clinical trial compares the effects of cervical HPV vs cytology (Pap smear) screening on the cumulative incidence of high-grade cervical intraepithelial neoplasia (CIN3+) detected at 48 months.
This JAMA Patient Page discusses the link between human papillomavirus infection and certain types of cancer.
This observational study uses incidence rates before and after adoption of the Affordable Care Act (ACA) to assess whether adoption of the ACA increased screening for breast, colorectal, and cervical cancer.
This Viewpoint posits that safely and effectively implementing consensus guidelines for Papanicolou and human papillomavirus testing for cervical cancer prevention requires accurate risk stratification of patients.
This population-based registry study determines the cervical intraepithelial neoplasia trends among female adolescents and young women after adjusting for changes in cervical screening practices that overlapped with HPV vaccination implementation.
This clinical evidence synopsis summarizes a Cochrane Systematic Review comparing the fertility and early pregnancy outcomes up to 24 weeks of gestation in women with a history of treatment vs those that have not received treatment.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: